The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study

Journal of the American College of Cardiology (2008) - Comment
pubmed: 18436114 doi: 10.1016/j.jacc.2007.11.079 issn: 0735-1097 issn: 1558-3597

Emile R. Mohler, Christie M. Ballantyne, Michael H. Davidson, Markolf Hanefeld, Luis M. Ruilope, Joel L. Johnson, Andrew Zalewski,